| The medical management of primary sclerosing cholangitis. | |
| | |
MedLine Citation:
|
PMID: 16496233 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Primary sclerosing cholangitis raises several challenges for the physician. These include the identification of a drug regimen that slows or reverses the progression of the disease, the effective management of the symptoms of cholestasis, and the prevention of complications of the disease, including the development of colorectal cancer. The most studied drug in PSC is ursodeoxycholic acid, which, despite a range of potentially valuable actions on the cholestatic liver, has not yet been proven to make a substantial change in the course of the disease. However, it may yet prove to be sufficiently effective in the prevention of colorectal neoplasia to be prescribable for this reason alone. Better progress has been made in identifying agents that can alleviate pruritus and prevent the progression of osteopenia. |
| | |
Authors:
|
Susan N Cullen; Roger W Chapman |
Related Documents
:
|
20012183 - Proanthocyanidins and the risk of colorectal cancer in italy. 17594933 - Cetuximab/targeted chemotherapy in an hiv-positive patient with metastatic colorectal c... 12014513 - Pubertal gynecomastia. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Seminars in liver disease Volume: 26 ISSN: 0272-8087 ISO Abbreviation: Semin. Liver Dis. Publication Date: 2006 Feb |
Date Detail:
|
Created Date: 2006-02-23 Completed Date: 2006-07-18 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8110297 Medline TA: Semin Liver Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 52-61 Citation Subset: IM |
Affiliation:
|
Wycombe General Hospital, High Wycombe, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cholagogues and Choleretics
/
therapeutic use* Cholangitis, Sclerosing / diagnosis, drug therapy* Clinical Trials as Topic Dose-Response Relationship, Drug Humans Immunosuppressive Agents / therapeutic use Treatment Outcome Ursodeoxycholic Acid / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Cholagogues and Choleretics; 0/Immunosuppressive Agents; 128-13-2/Ursodeoxycholic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Primary sclerosing cholangitis and cholangiocarcinoma.
Next Document: Primary sclerosing cholangitis: the role of endoscopic therapy.